Anniina E. M. Färkkilä - Gynecology

Author Information

Anniina E. M. Färkkilä is a distinguished researcher affiliated with the Children's Hospital, University of Helsinki, and Helsinki University Hospital in Finland. Her extensive work in the field of Obstetrics and Gynecology has positioned her as a prominent figure in medical research, particularly within the context of ovarian cancer and related domains.

Research Contributions

Anniina E. M. Färkkilä has made significant contributions to the understanding of gynecological cancers, with a focus on ovarian cancer. Her research encompasses the tumor microenvironment, genomics, and therapeutic responses, including the exploration of PARP inhibitors and their role in cancer treatment. Her studies have advanced the knowledge of tumor-immune interactions and the genomic landscape of cancer cells, offering insights into treatment resistance and potential therapeutic strategies.

Aliases

Anniina E. M. Färkkilä is known by several aliases, including A. Färkkilä, Anniina Em Färkkilä, and Anniina Färkkilä. These variations are used interchangeably in academic and research publications.

Publication and Citation Metrics

Metric	Value
Total Papers Published	84
Total Citation Count	2083
H-index	25

Publications:

Abstract P2-07-13: High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlatives of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancer

DOI: 10.1158/1538-7445.sabcs21-p2-07-13

Year: 2022

Analysis of Non-Relapsed and Relapsed Adult Type Granulosa Cell Tumors Suggests Stable Transcriptomes during Tumor Progression

DOI: 10.3390/cimb44020048

Year: 2022

Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer

DOI: 10.1038/s41467-022-28389-3

Year: 2022

A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer

DOI: 10.1038/s41467-021-25904-w

Year: 2021

Adult‐type granulosa cell tumor of the ovary: a FOXL2‐centric disease

DOI: 10.1002/cjp2.198

Year: 2021

Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells

DOI: 10.1158/0008-5472.CAN-20-2912

Year: 2021

Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation.

DOI: 10.1016/j.ccell.2021.10.008

Year: 2021

A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors

DOI: 10.1038/s43018-021-00203-x

Year: 2021

Optimized detection of somatic allelic imbalances specific for homologous recombination deficiency improves the prediction of clinical outcomes in ovarian cancer

DOI: 10.1101/2021.08.19.456809

Year: 2021

Abstract 2059: AI - optimized genomic homologous recombination deficiency test (HRDScar) to predict platinum and PARP inhibitor responses in high-grade serous ovarian cancer

DOI: 10.1158/1538-7445.AM2021-2059

Year: 2021

What are Sanitary Pads?

What Diagnostic Tests Do Urogynecologists Use?

What Are Mortality Rates in Gynecology?

Why is Active Listening Important in Gynecology?

Are There Any Special Considerations for Women with Vaginal Infections?

How Do Genetic Factors Affect Reproductive Health?

Is Laser Hair Removal Safe for the Genital Area?

What Types of Genetic Tests Are Available?

Can Enzyme Supplements Help with Menstrual Disorders?

What are Common Postoperative Instructions?

Partnered Content Networks

Relevant Topics